The anaerobic gut bacterium Akkermansia muciniphila is a well-characterised member of the mucosal microbiota and has shown to be a gut symbiont in human. A. muciniphila has been negatively associated with obesity and its associated metabolic disorders in various human cohorts while treatment with A. muciniphila cells reversed highfat diet-induced obesity and its associated metabolic disorders in mouse models. Therefore, administration of A. muciniphila has been suggested as a possible new therapeutic treatment for these omnipresent diseases. Here we describe a potentially scalable workflow for the preparation and preservation of high numbers of viable cells of A. muciniphila obtained from 1 l laboratory scale growth under strict anaerobic conditions for therapeutic interventions. This resulted in viable A. muciniphila cells with high yields and very high stability, with up to 97.9±4.5% survival for a time period of 1 year at -80 °C in glycerol-amended medium. Moreover, various quality assessment and control procedures were developed to ensure the use of viable cells of A. muciniphila. Several microscopic, culturing, and molecular approaches were applied to monitor the presence, abundance and recovery of A. muciniphila before, during, and after its administration to high-fat treated mice. We show that viable A. muciniphila cells can be recovered from caecal and colon content (up to 1×1010 cells/g), testifying for the efficiency of the described workflow.
RESEARCH ARTICLE
Preparation and preservation of viable Akkermansia muciniphila cells for therapeutic interventions
J.P. Ouwerkerk Related information
1Laboratory of Microbiology, Wageningen University, Dreijenplein 10, 6703 HB Wageningen, the Netherlands.
, S. Aalvink Related information1Laboratory of Microbiology, Wageningen University, Dreijenplein 10, 6703 HB Wageningen, the Netherlands.
, C. Belzer Related information1Laboratory of Microbiology, Wageningen University, Dreijenplein 10, 6703 HB Wageningen, the Netherlands.
, W.M. De Vos Related information1Laboratory of Microbiology, Wageningen University, Dreijenplein 10, 6703 HB Wageningen, the Netherlands.
2Department of Veterinary Biosciences, University of Helsinki, P.O. Box 66, 00014 Helsinki, Finland.
3Department of Bacteriology and Immunology, and Research Programs Unit Immunology, University of Helsinki, P.O. Box 21, 00014 Helsinki, Finland.
*willem. devos@wur. nl
2Department of Veterinary Biosciences, University of Helsinki, P.O. Box 66, 00014 Helsinki, Finland.
3Department of Bacteriology and Immunology, and Research Programs Unit Immunology, University of Helsinki, P.O. Box 21, 00014 Helsinki, Finland.
*willem.
Beneficial Microbes: 8
(2)- Pages: 163 - 169
Published Online: January 24, 2017
Abstract
Keywords: therapeutic microbe, stability, viability, laboratory scale production, delivery
2022 Journal Impact Factor
5.4
source: Journal Impact Factor 2023™ from Clarivate™
Institutional Offers
For institutional orders, please contact [email protected].
-
A.A. Hibberd, C.C. Yde, M.L. Ziegler, A.H. Honoré, M.T. Saarinen, S. Lahtinen, B. Stahl, H.M. Jensen and L.K. Stenman
-
E.E. Blaak, E.E. Canfora, S. Theis, G. Frost, A.K. Groen, G. Mithieux, A. Nauta, K. Scott, B. Stahl, J. van Harsselaar, R. van Tol, E.E. Vaughan and K. Verbeke
-
K. Venema, J. Verhoeven, C. Beckman and D. Keller
-
E. Arvidsson Nordström, C. Teixeira, C. Montelius, B. Jeppsson and N. Larsson
-
J.E. Haarhuis, A. Kardinaal and G.A.M. Kortman
-
E.E. Blaak, E.E. Canfora, S. Theis, G. Frost, A.K. Groen, G. Mithieux, A. Nauta, K. Scott, B. Stahl, J. van Harsselaar, R. van Tol, E.E. Vaughan and K. Verbeke
-
K. Lippert, L. Kedenko, L. Antonielli, I. Kedenko, C. Gemeier, M. Leitner, A. Kautzky-Willer, B. Paulweber and E. Hackl
-
K. Tsilingiri and M. Rescigno
-
M. Ozen and E.C. Dinleyici
-
Y. Kobayashi, T. Kuhara, M. Oki and J.-Z. Xiao